--- schema_version: "secwatch.filing_event.v1" accession: "0000950170-23-013745" form_type: "8-K" ticker: "PSTV" cik: "0001095981" company_name: "PLUS THERAPEUTICS, INC." filed_at: "2023-04-21T23:59:59+00:00" generated_at: "2026-06-16T21:06:44.441708+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.65 calibrated_materiality_score: 0.65 confidence: "high" source: SEC EDGAR --- # Plus Therapeutics stockholders approve reverse stock split authorization at annual meeting ## Summary - Reverse stock split approved; ratio of 1:3 to 1:15 to be set by board at a later date. - All six director nominees elected, including Marc Hedrick and Howard Clowes. - BDO USA ratified as independent auditor for 2023; say-on-pay passed with 4.58M for. - Stockholders favored one-year frequency for future advisory votes on executive compensation. - Amended 2020 Stock Incentive Plan approved; preferred stock (50M votes) voted proportionally on split. ## SEC filing metadata - accession: 0000950170-23-013745 - form_type: 8-K - ticker: PSTV - cik: 0001095981 - company_name: PLUS THERAPEUTICS, INC. - filed_at: 2023-04-21T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.65 - calibrated_materiality_score: 0.65 - confidence: high - sec_items: 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/0000950170-23-013745-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/pstv-20230420.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000950170-23-013745 - JSON: https://secwatch.observer/filing/0000950170-23-013745.json - Plain text: https://secwatch.observer/filing/0000950170-23-013745.txt ## Key facts - Shareholder Votes PLUS THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on the compensation of the Company’s named executive officers at the 2023-04-20 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-04-20 source text: 3. Proposal to provide a non-binding advisory vote on the compensation of the Company’s named executive officers: For Against Abstain 4,580,421 1,735,989 179,468 evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/0000950170-23-013745-index.htm - Shareholder Votes PLUS THERAPEUTICS, INC. shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding shares of the Company’s common stock, at a ratio of not less than 1-for-3 and not greater than 1-for-15 at the 2023-04-20 meeting. - Proposal: reverse split - Outcome: passed - Meeting: 2023-04-20 source text: 5. Proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from one-for-three (1:3) to one-for-fifteen (1:15): For Against Abstain 52,798,957 12,179,757 517,698 evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/0000950170-23-013745-index.htm - Shareholder Votes PLUS THERAPEUTICS, INC. shareholders approved Election of six directors to serve until the 2024 annual meeting or until their successors are duly elected and qualified at the 2023-04-20 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-04-20 source text: 1. Proposal to elect six directors to serve until the 2024 annual meeting or until their successors are duly elected and qualified: For Withheld Broker Non-Votes Howard Clowes 5,306,629 1,189,249 9,000,533 An van Es-Johansson 5,387,484 1,108,394 9,000,533 Richard J. Hawkins 5,364,397 1,131,481 9,000,533 Marc H. Hedrick, M.D. 5,700,185 795,693 9,000,533 Robert Lenk 5,308,285 1,187,593 9,000,533 Greg Petersen 5,675,200 820,678 9,000,533 evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/0000950170-23-013745-index.htm - Shareholder Votes PLUS THERAPEUTICS, INC. shareholders approved Ratification of the appointment of BDO USA, LLP as the Company’s independent auditors for the 2023 fiscal year at the 2023-04-20 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-04-20 source text: 2. Proposal to ratify the appointment of BDO USA, LLP as the Company’s independent auditors for the 2023 fiscal year: For Against Abstain 14,681,590 617,972 196,849 evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/0000950170-23-013745-index.htm - Shareholder Votes PLUS THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on the frequency of holding future non-binding advisory votes on executive officer compensation at the 2023-04-20 meeting. - Proposal: say on pay frequency - Outcome: passed - Meeting: 2023-04-20 source text: 4. Proposal to provide a non-binding advisory vote on the frequency of holding future non-binding advisory votes on executive officer compensation: One Year Two Years Three Years Abstain 5,695,824 105,972 401,874 292,208 evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/0000950170-23-013745-index.htm - Shareholder Votes PLUS THERAPEUTICS, INC. shareholders approved Approval of the third amendment and restatement of the Company’s 2020 Stock Incentive Plan at the 2023-04-20 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2023-04-20 source text: 6. Proposal to approve the third amendment and restatement of the Company’s 2020 Stock Incentive Plan: For Against Abstain 4,279,475 2,112,637 103,766 evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/0000950170-23-013745-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.